Rhinigine

Rhinigine may be available in the countries listed below.

Ingredient matches for Rhinigine

Loratadine

Loratadine is reported as an ingredient of Rhinigine in the following countries:

• South Africa

International Drug Name Search

Bilumide

Bilumide may be available in the countries listed below.

Ingredient matches for Bilumide

Bicalutamide

Bicalutamide is reported as an ingredient of Bilumide in the following countries:

• Greece

International Drug Name Search

Nicotine Polacrilex

Ingredient matches for Nicotine Polacrilex

Nicotine

Nicotine Polacrilex (USAN) is known as Nicotine in the US.

International Drug Name Search

Glossary

USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Virpes

Virpes may be available in the countries listed below.

Ingredient matches for Virpes

Acyclovir

Aciclovir is reported as an ingredient of Virpes in the following countries:

• Oman

International Drug Name Search

Nimodilat

Nimodilat may be available in the countries listed below.

Ingredient matches for Nimodilat

Nimodipine

Nimodipine is reported as an ingredient of Nimodilat in the following countries:

• Argentina

International Drug Name Search

Antibiotrex

Antibiotrex may be available in the countries listed below.

Ingredient matches for Antibiotrex

Erythromycin

Erythromycin is reported as an ingredient of Antibiotrex in the following countries:

• France

Isotretinoin

Isotretinoin is reported as an ingredient of Antibiotrex in the following countries:

• France

International Drug Name Search

Klaritromycin STADA

Klaritromycin STADA may be available in the countries listed below.

Ingredient matches for Klaritromycin STADA

Clarithromycin

Clarithromycin is reported as an ingredient of Klaritromycin STADA in the following countries:

• Sweden

International Drug Name Search

Razor

Razor may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Razor

Ivermectin

Ivermectin is reported as an ingredient of Razor in the following countries:

• Australia

Praziquantel

Praziquantel is reported as an ingredient of Razor in the following countries:

• Australia

International Drug Name Search

Céliprolol Ranbaxy

Céliprolol Ranbaxy may be available in the countries listed below.

Ingredient matches for Céliprolol Ranbaxy

Celiprolol

Celiprolol hydrochloride (a derivative of Celiprolol) is reported as an ingredient of Céliprolol Ranbaxy in the following countries:

• France

International Drug Name Search

Dulera

Dulera is a brand name of formoterol/mometasone, approved by the FDA in the following formulation(s):

DULERA (formoterol fumarate; mometasone furoate - aerosol, metered; inhalation)

• 
  Manufacturer: SCHERING
  
  Approval date: June 22, 2010
  
  Strength(s): 0.005MG/INH;0.1MG/INH ^[RLD], 0.005MG/INH;0.2MG/INH ^[RLD]

Has a generic version of Dulera been approved?

No. There is currently no therapeutically equivalent version of Dulera available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dulera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of mometasone furoate for treating lower airway passage and lung diseases
  Patent 5,889,015
  Issued: March 30, 1999
  Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,057,307
  Issued: May 2, 2000
  Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Chlorofluorocarbon-free mometasone furoate aerosol formulations
  Patent 6,068,832
  Issued: May 30, 2000
  Inventor(s): Berry; Julianne & Sequeira; Joel A. & Chaudry; Imtiaz A.
  Assignee(s): Schering Corporation
  The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.
  
  Patent expiration dates:
  
  
  • August 27, 2017
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,677,323
  Issued: January 13, 2004
  Inventor(s): Joel A.; Sequeira & Francis M.; Cuss & Keith B.; Nolop & Imtiaz A.; Chaudry & Nagamani; Nagabhushan & James E.; Patrick & Mitchell; Cayen
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  



• 
  Combinations of formoterol and mometasone furoate for asthma
  Patent 7,067,502
  Issued: June 27, 2006
  Inventor(s): Hassan; Ian Francis & Clarke; Jeremy Guy & Danahay; Henry Luke
  Assignee(s): Novartis AG
  A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
  
  Patent expiration dates:
  
  
  • May 21, 2020
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  



• 
  Combination of formoterol and mometasone furoate for asthma
  Patent 7,566,705
  Issued: July 28, 2009
  Inventor(s): Hassan; Ian F & Clarke; Jeremy G & Danahay; Henry L
  Assignee(s): Novartis AG
  A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
  
  Patent expiration dates:
  
  
  • May 8, 2020
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 22, 2013 - NEW COMBINATION
  
  

See also...

• Dulera Consumer Information (Drugs.com)
• Dulera Inhalation Aerosol Consumer Information (Wolters Kluwer)
• Dulera Consumer Information (Cerner Multum)
• Dulera Advanced Consumer Information (Micromedex)
• Mometasone/Formoterol Inhalation Aerosol Consumer Information (Wolters Kluwer)
• Formoterol and mometasone Consumer Information (Cerner Multum)
• Mometasone and formoterol Inhalation Advanced Consumer Information (Micromedex)

Co-Quinapril Sandoz

Co-Quinapril Sandoz may be available in the countries listed below.

Ingredient matches for Co-Quinapril Sandoz

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Co-Quinapril Sandoz in the following countries:

• Belgium

Quinapril

Quinapril hydrochloride (a derivative of Quinapril) is reported as an ingredient of Co-Quinapril Sandoz in the following countries:

• Belgium

International Drug Name Search

Xylocaina Viscosa

Xylocaina Viscosa may be available in the countries listed below.

Ingredient matches for Xylocaina Viscosa

Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Xylocaina Viscosa in the following countries:

• Argentina


• Chile

International Drug Name Search

Dermal Necrosis Medications

Topics under Dermal Necrosis

• Dermal Necrosis, Prophylaxis (10 drugs)

• Dermal Necrosis, Treatment (1 drug)

Drug List: